---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093884"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:05:31.336398+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Equillium Q2 net income $0.5M, revenue $13.9M; Ono itolizumab option decision by Oct 2024

## Summary
- Net income $0.5M ($0.01 EPS) vs net loss $3.3M in Q2 2023; revenue $13.9M (all from Ono collaboration), up from $9.1M.
- Cash $33.3M, up $1.0M from Q1 2024; expects to fund operations for at least 12 months, adjusting spending if needed.
- Ono option to acquire itolizumab rights decision by Oct 2024; if exercised, Equillium receives JPY 5B (~$35M) plus up to $101.4M milestones.
- Phase 3 EQUATOR study (aGVHD) IDMC recommends proceed after positive interim review; no safety or futility concerns.
- Positive topline data from Phase 1b EQUALISE (lupus nephritis) and Phase 2 EQ101 (alopecia areata); preparing Phase 2b study in 2025.

## SEC filing metadata
- accession: 0000950170-24-093884
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000095017024093884/0000950170-24-093884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000095017024093884/eq-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093884
- JSON: https://secwatch.observer/filing/0000950170-24-093884.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093884.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.